Author

E. Fewings

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. Prahallad· 1 shared A. Ruiz-Saenz· 1 shared B. Hann· 1 shared B. Pan· 1 shared C. A. Dreyer· 1 shared C. Cowdrey· 1 shared C. E. Atreya· 1 shared C. Kuppe· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Prahallad

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF(V600E) colorectal tumors

A. Ruiz-Saenz, C. E. Atreya, C. Wang, B. Pan, C. A. Dreyer, D. Brunen, A. Prahallad, D. P. Munoz, D. J. Ramms, V. Burghi, D. S. Spassov, E. Fewings, Y. C. Hwang, C. Cowdrey, C. Moelders, , J.-P. Coppe

This study identifies a SRC-relayed COX2-inflammatory program that drives resistance to BRAF/MEK/EGFR therapies in BRAFV600E colorectal tumors and shows that co-targeting COX2 improves therapeutic outcomes.

bioRxiv · Oct 20, 2022 · PreprintCancer Biology

Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell epitope mapping

F. Schreibing, M. Hannani, F. Ticconi, E. Fewings, J. S. Nagai, M. Begemann, C. Kuppe, I. Kurth, J. Kranz, D. Frank, T. M. Anslinger, P. Ziegler, T. Kraus, J. Enczmann, V. Balz, , R. Kramann

This study identifies an immunogenic CD8+ T cell epitope associated with severe SARS-CoV-2 infection and characterizes its pathological features.

bioRxiv · Mar 3, 2021 · PreprintImmunology